Scanning the Horizon for Accessibility to ATMPs

3D illustration of embryonic stem cells under microscope

Advanced Therapy Medicinal Products (ATMPs):

  • Gene therapy medicines
  • Somatic-cell therapy medicines
  • Tissue-engineered medicines
  • Combined ATMPs

are a fairly new class of biological products, providing innovative therapeutic solutions in human medicine. ATMPs offer huge potential for the treatment of diseases (cancer, rare diseases, etc.) and injuries for which limited, or no alternative treatment options exist. They give the possibility to substantially improve the therapy for many diseases and conditions and promise a great positive impact to patient’s health and the future of medicine in general.

ATMPs bring life-changing benefits for patients and their families. Moreover, they are a long-waited hope for treatment and control of diseases and conditions for which there is no beneficial therapy or treatment options are not available yet. Even though these therapies offer amazing opportunities, some challenges related to manufacturing, market access, reimbursement and patient access are also present.

Are ATMPs the start of a new era in medicine and can we put its beginning for Bulgarian patients? We will raise these and even more questions, and will look for answers in a seminar on the topic “Scanning the Horizon for Accessibility to Cell and Gene Therapies (ATMPs)”, which will be held on 13th May 2021 between 15:30 and 17:30, UTC +3.

Different experts, including clinicians, HTA specialists, representatives of relevant institutions (National Health Insurance Fund, National Council on Prices and Reimbursement of Medicinal Products), academia structures and patient organizations will discuss advantages, potential, challenges, prospects, opportunities, and difficulties in market authorization, reimbursement and patients’ access to promising innovations in healthcare – advanced therapy medicinal products (ATMPs).
By uniting knowledge and emotions, the seminar “Scanning the Horizon for Accessibility to Cell and Gene Therapies (ATMPs)” will focus on the opportunities, potential and challenges of ATMPs.

The event will be conducted as per the following agenda:

  • Opening
  • ATMPs – introduction, Assoc. Prof. Borislav Borissov, MD, PhD, MBA, DSci
  • Keynote Lecture – Prof. Mondher Toumi, MD, MsC, PhD, University of Aix – Marseille, France
  • Patient ‘s Story – A patient’s view of CAR-T Cell Therapy by Jonathan Clark (video)
  • ATMPs in Bulgaria: opportunities and challenges – expert discussion
  • Closing remarks and next steps

The seminar is a part of the scientific program of topics and events of Biotech Atelier 2021 and is conducted with the financial support of Novartis Bulgaria.

Skip to content